Emmanuel Lacroix
Direttore/Membro del Consiglio presso Lumos Pharma Sub, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Richard Hawkins | M | 75 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 14 anni |
| Jean-Pierre Latere | M | 49 |
EsoBiotec SA
 EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | 4 anni |
| Robert Lyne | M | 41 |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 3 anni |
| Michel Allé | M | 74 |
Université Libre de Bruxelles
| 27 anni |
| Ari Nowacek | M | - |
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | - |
| Robert A. Heft | M | 69 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Blaine McKee | M | 59 |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | 4 anni |
| Roy Ervin Twyman | M | 68 |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Peregrine Moncreiffe | M | 73 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | - |
| Lazar Dimitrov | M | - |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| An van Es-Johansson | M | 64 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 3 anni |
| Debra Stephanie Barker | M | 61 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 2 anni |
| Maureen O'Connell | F | 62 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 3 anni |
| Morten Graugaard Døssing | M | - |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Delphine Hajaji | F | - |
UCB Ventures (Private Equity)
 UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | 5 anni |
| Peter G. Linde | M | 57 |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | 2 anni |
| Steven Biesmans | M | - |
UCB Ventures (Private Equity)
UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | 3 anni |
| Maeve Duffy | M | - |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Tom Davidson | M | - |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 1 anni |
| Jade Fletcher | F | - |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | - |
| Paul Rennert | M | - |
EsoBiotec SA
EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | 3 anni |
| Andrew P. Smith | M | 61 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 2 anni |
| Kathleen Fanning | F | - |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | - |
| Jonathan R. Savidge | M | - |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Steven Gillis | M | 71 |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | - |
| Carole Nüchterlein | F | 62 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 7 anni |
| Kevin Lalande | M | 51 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Ed Mathers Mathers | M | 64 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Jean Combalbert | M | - |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Emmett Cunningham | M | 63 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Christina Takke | M | 54 |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | - |
| Angela Ene | F | - |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 2 anni |
| Erica Whittaker | M | - |
UCB Ventures (Private Equity)
UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | - |
| Michel Briejer | M | - |
EsoBiotec SA
EsoBiotec SA Miscellaneous Commercial ServicesCommercial Services EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020. | 3 anni |
| Isaac Kohlberg | M | 71 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | 3 anni |
| Mark Goldberg | M | 69 |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | - |
| Fiona MacLaughlin | M | - |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | 4 anni |
| Cameron Wheeler | M | 45 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Didier Matray | M | 73 |
University of Liege
| 32 anni |
| Curt Dewan | M | - |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| David Ummels | M | - |
University of Liege
| 10 anni |
| Tanguy Cornet | M | - |
Université Libre de Bruxelles
| 5 anni |
| Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 anni |
| Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 4 anni |
| Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 anni |
| Daniël van Nieuwenhove | M | - |
Université Libre de Bruxelles
| 4 anni |
| Éric Reiter | M | - |
University of Liege
| 3 anni |
| Frederic Halkin | M | - |
Université Libre de Bruxelles
| 1 anni |
| William Ledger | M | 57 |
Université Libre de Bruxelles
| 1 anni |
| Alain Kupchik | M | - |
Université Libre de Bruxelles
| 5 anni |
| Pascal Keutgens | M | - |
University of Liege
| 5 anni |
| Huong Giang Thi Luong | F | 57 |
Université Libre de Bruxelles
| 2 anni |
| Daniel Marechal | M | - |
University of Liege
| 3 anni |
| Jean-Pierre Verlaine | M | - |
University of Liege
| 2 anni |
| Ayuporn Karnasuta | F | - |
Université Libre de Bruxelles
| 2 anni |
| Benoît Taymans | M | - |
Université Libre de Bruxelles
| 4 anni |
| Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 anni |
| Aminata Kaké | F | 47 |
Université Libre de Bruxelles
| 4 anni |
| Pierre-Yves Collée | M | 49 |
University of Liege
| 4 anni |
| Daniel Malek | M | - |
Université Libre de Bruxelles
| 5 anni |
| Nikkolaos Antimissaris | M | 55 |
University of Liege
| 4 anni |
| Gonzalo Tradacete Gallart | M | - |
Université Libre de Bruxelles
| 5 anni |
| Soumya Chandramouli | F | 46 |
University of Liege
| 4 anni |
| Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 anni |
| Nathalie Thunus | F | - |
University of Liege
| 4 anni |
| Samuli Kuusela | M | - |
IMD College
| 1 anni |
| Nourredine Chinek | M | - |
Université Libre de Bruxelles
| 4 anni |
| Herjan Coelingh Bennink | M | - |
Université Libre de Bruxelles
| 8 anni |
| Valérie Gordenne | F | 51 |
University of Liege
| 4 anni |
| Christine D. Franquin | F | - |
University of Liege
| 3 anni |
| Denis Hermesse | M | 54 |
University of Liege
| 4 anni |
| Matthias de Raeymaeker | M | 49 |
Université Libre de Bruxelles
| 2 anni |
| Antoine Duchateau | M | 70 |
Université Libre de Bruxelles
| 1 anni |
| Robert Kiss | M | - |
Université Libre de Bruxelles
| 2 anni |
| Francis Darro | M | - |
Université Libre de Bruxelles
| 2 anni |
| Yvan de Launoit | M | - |
Université Libre de Bruxelles
| 7 anni |
| Frédéric Zoller | M | - |
Université Libre de Bruxelles
| 4 anni |
| Mathieu Francois Pierre Pasture | M | - |
Université Libre de Bruxelles
| 1 anni |
| Vincent Marville | M | - |
University of Liege
| 4 anni |
| Stephane Berghmans | M | 55 |
University of Liege
| 3 anni |
| Gilles-Olivier Moury | M | - |
University of Liege
| 4 anni |
| Pierre Jacquet | M | 57 |
University of Liege
| 3 anni |
| Amelie Coens | F | - |
Université Libre de Bruxelles
| 4 anni |
| Fabrizio Giannotta | M | - |
University of Liege
| 3 anni |
| Benjamin Gigot | M | - |
Université Libre de Bruxelles
| 6 anni |
| Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 1 anni |
| Lamia Tazi | F | 47 |
University of Liege
| 4 anni |
| Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 anni |
| Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 anni |
| Bernard Stas | M | - |
University of Liege
| 1 anni |
| Tuan Van Nguyen | M | 54 |
Université Libre de Bruxelles
| 2 anni |
| Stéphanie Vanden Broecke | F | - |
Université Libre de Bruxelles
| 3 anni |
| Patricia Vangeel | F | - |
University of Liege
| 4 anni |
| Denis Goffaux | M | 57 |
University of Liege
| 4 anni |
| Dimitri Liquet | M | - |
University of Liege
| 5 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Belgio | 69 | 72.63% |
| Stati Uniti | 16 | 16.84% |
| Regno Unito | 9 | 9.47% |
| Sud Africa | 1 | 1.05% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Emmanuel Lacroix
- Contatti personali
